Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 22, Number 10—October 2016
Letter

Recombinant Enterovirus A71 Subgenogroup C1 Strains, Germany, 2015

On This Page
Figures
Article Metrics
32
citations of this article
EID Journal Metrics on Scopus

Cite This Article

To the Editor: Enterovirus A71 (EV-A71) strains circulate worldwide, and numerous outbreaks have been reported from Asia, Australia, Europe, and America (1). Symptomatic infections range from mild febrile illness or characteristic diseases such as hand, foot and mouth disease to severe neurologic disorders such as meningitis/encephalitis and acute flaccid paralysis. EV-A71 infections are usually asymptomatic and self-limiting but can also result in life-threatening complications such as pulmonary edema and cause death, predominantly in children <5 years of age. On the basis of viral protein 1 (VP1) sequences, 3 genogroups (A, B, C), including different subgenogroups (B0–B5, C1–C5), have been defined (2,3). Additional genogroups (D, E, F, G) have been proposed (4,5). In Europe, C1 and C2 strains have circulated predominantly within the past 2 decades, and recent introduction of C4 strains has been reported (6,7). Within subgenogroup C1, a lineage is replaced by the subsequent lineage over time (8).

National enterovirus surveillance (EVSurv) in Germany monitors polio-free status by testing fecal or cerebrospinal fluid (CSF) samples from hospitalized patients with suspected meningitis/encephalitis or acute flaccid paralysis. Enterovirus typing, using molecular and virologic methods, is performed within a laboratory network for enterovirus diagnostics. Since 2006, ≈2,500 samples have been tested annually; 25%–30% were enterovirus positive. Of the typed strains, 0.8%–12.7% were identified as EV-A71 (2006, 0.8%; 2007, 6.8%; 2008, 0.9%; 2009, 3.4%; 2010, 12.7%; 2011, 2.3%; 2012, 2.8%; 2013, 8.6%; 2014, 2.7%), indicating peaks with increased EV-A71 detection rates. Molecular characterization based on the VP1 region of a subset of EV-A71–positive samples revealed that C2 was the predominant subgenogroup in Germany from 2006 to 2014. Subgenogroups B5, C1, and C4 have also been identified, but less frequently (Technical Appendix Table 3).

Figure

Thumbnail of Phylogenetic tree based on complete viral protein 1 (VP1) nucleotide sequences of the strains identified within the German enterovirus surveillance (bold) and a representative set of enterovirus A71 strains available from GenBank (891 bases, corresponding to nucleotide positions 2439–3329 in the prototype BrCr ETU22521). The tree was constructed by using the neighbor-joining method (Kimura 2-parameter model) with 1,000 replicates through MEGA 6.06 (http://www.megasoftware.net/). Cox

Figure. Phylogenetic tree based on complete viral protein 1 (VP1) nucleotide sequences of the strains identified within the German enterovirus surveillance (bold) and a representative set of enterovirus A71 strains available from...

In 2015, a total of 419 samples tested enterovirus positive within EVSurv. Of these, 43 fecal specimens and 1 CSF specimen tested EV-A71 positive (11.2% of the typed enteroviruses); these samples were obtained from patients with signs of meningitis/encephalitis hospitalized in 25 secondary and tertiary care hospitals from 13 of 16 federal states of Germany. Thirty-six strains were further characterized at the National Reference Centre for Poliomyelitis and Enteroviruses (Technical Appendix Table 2). Seventeen strains were identified as C2 by using the RIVM Enterovirus Genotyping Tool Version 1.0 (http://www.rivm.nl/mpf/enterovirus/typingtool) based on the VP1 region sequences (9). Sequence analyses of the remaining 19 strains revealed highest nucleotide identity (90%–93%) with recently circulating C1 strains from GenBank. Phylogenetic analysis that used the neighbor-joining tree algorithm showed separate clustering of these strains within the C1 subgenogroup (Figure). In contrast to the VP1 tree, phylogenetic analyses based on the 5′ untranslated region (UTR) and the P2 and P3 regions revealed different clustering of the German 2015 EV-A71 C1-like group (Technical Appendix Figure). In line with these phylogenetic tree topologies, we found highest nucleotide identities to subgenogroup B3 and C2-like strains for 5′ UTR (both 90%), whereas P2 and P3 regions showed highest nucleotide identity of 82% and 84%, respectively, with C4 strains identified in China. We found no specific amino acid changes within the conserved major antigenic sites of the capsid proteins. However, we observed a V16M change in VP1. Few EV-A71 strains (all B1) also carry a methionine at this position, including the outbreak strains from Bulgaria (1975) and Hungary (1978). Also, we identified a valine residue at position 262 in VP1. Tee et al. have proposed that toggling of amino acids isoleucine and valine at this position in recent C1 lineages generates antigenic novelty (8). Within the 5′ UTR, a C526U change has been proposed to affect replication efficiency (10). All isolates belonging to the new EV-A71 C1 variant carried uracil at this position. In addition, we found a 2-nucleotide deletion within the spacer 2 region between the internal ribosome entry site and the coding region, similar to the EV-A71 prototype BrCr and the C2-like strains (GenBank accession nos. HM622392, HM622391, JQ280307) (data available on request).

Our findings highlight the need for molecular surveillance of enteroviruses to identify new variant strains with potential for increased virulence and pathogenicity. One limitation of the EVSurv is the lack of detailed clinical data because the request form deliberately asks for only basic cardinal symptoms justifying the clinical suspicion of meningitis/encephalitis or acute flaccid paralysis. Nevertheless, all patients had been hospitalized, suggesting severe disease. Besides characteristic symptoms (including nuchal rigidity, headache, fever, and vomiting), cerebral seizures, myoclonia, ataxia, petechiae, and stomatitis were also mentioned for some patients tested for the new variant C1-like strains described here. All patients, but 1, were <5 years of age (Technical Appendix Table 1). Therefore, pediatricians, in particular, should be aware of this new recombinant, potentially more pathogenic, strain and intensify diagnostic work-ups to better monitor EV-A71 circulation. In addition to CSF samples, fecal samples, throat swab specimens, and samples related to other clinical prodromes (e.g., vesicle fluids in cases of hand, foot and mouth disease) should be obtained. Particular attention should be paid to measures in daycare centers to prevent large outbreaks of enterovirus-associated meningitis/encephalitis.

Top

Acknowledgments

We thank all clinicians participating in the Germany enterovirus surveillance and technical staff in all laboratories for excellent performance.

The following authors contributed to this work through the national laboratory network for enterovirus diagnostics (LaNED): Jörg Hofmann, Department of Virology, Labor Berlin–Charite Vivantes GmbH, Berlin; Harald Heider, Department of Virology, Labor Berlin–Charite Vivantes GmbH, Berlin, Germany; Ursula Reif, Saxony State Laboratory of Health and Veterinary Affairs Department of Medical Microbiology and Hygiene, Dresden, Germany; Klaus Korn, Virology Institute–Clinical and Molecular Virology University Hospital Erlangen and Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, Germany; Holger F. Rabenau, Institute of Medical Virology University Hospital Frankfurt, Frankfurt, Germany; Andreas Wille, Institute for Hygiene and Environment, Medical Microbiology, Hamburg, Germany; Armin Baillot, Governmental Institute of Public Health of Lower Saxony, Hannover, Germany; Aleksandra Pettke, Institute of Medical Microbiology–Clinical Virology University Hospital, Muenster, Germany; Joachim Kühn, Institute of Medical Microbiology–Clinical Virology University Hospital, Muenster; Nikolaus Ackermann, Bavarian Health and Food Safety Authority, Oberschleissheim, Germany; Christiane Ramelow, Ernst von Bergmann, Diagnostic GmbH, Potsdam, Germany; Ralph Hahn, Laboratory Prof. G. Enders MVZ and Institute of Virology, Infectious Diseases and Epidemiology e.V., Stuttgart, Germany; Germany; Martin Enders, Laboratory Prof. G. Enders MVZ and Institute of Virology, Infectious Diseases and Epidemiology e.V., Stuttgart; Maja Adam, Governmental Institute of Public Health of Baden-Wuerttemberg (LGA), Stuttgart; Detlef Michel, Institute of Virology, University Medical Center Ulm, Ulm, Germany; Axel Schubert, Institute of Virology, University Medical Center Ulm, Ulm; Benedikt Weißbrich, Institute of Virology and Immunobiology University of Wuerzburg, Wuerzburg, Germany; Christiane Prifert, Institute of Virology and Immunobiology University of Wuerzburg, Wuerzburg.

Top

Sindy Böttcher, Patrick E. Obermeier, Katrin Neubauer, Sabine DiedrichComments to Author , and the Laboratory Network for Enterovirus Diagnostics
Author affiliations: Robert Koch Institute, Berlin, Germany

Top

References

  1. Yip  CC, Lau  SK, Woo  PC, Yuen  KY. Human enterovirus 71 epidemics: what’s next? Emerg Health Threats J. 2013;6:19780. DOIPubMedGoogle Scholar
  2. Brown  BA, Oberste  MS, Alexander  JP Jr, Kennett  ML, Pallansch  MA. Molecular epidemiology and evolution of enterovirus 71 strains isolated from 1970 to 1998. J Virol. 1999;73:996975.PubMedGoogle Scholar
  3. McMinn  PC. Recent advances in the molecular epidemiology and control of human enterovirus 71 infection Curr Opin Virol. 2012;2:199205. DOIPubMedGoogle Scholar
  4. Saxena  VK, Sane  S, Nadkarni  SS, Sharma  DK, Deshpande  JM. Genetic diversity of enterovirus A71, India. Emerg Infect Dis. 2015;21:1236.
  5. Bessaud  M, Razafindratsimandresy  R, Nougairède  A, Joffret  ML, Deshpande  JM, Dubot-Pérès  A, Molecular comparison and evolutionary analyses of VP1 nucleotide sequences of new African human enterovirus 71 isolates reveal a wide genetic diversity. PLoS One. 2014;9:e90624. DOIPubMedGoogle Scholar
  6. Fischer  TK, Nielsen  AY, Sydenham  TV, Andersen  PH, Andersen  B, Midgley  SE. Emergence of enterovirus 71 C4a in Denmark, 2009 to 2013. Euro Surveill. 2014;19:p=20911. DOIPubMedGoogle Scholar
  7. Hassel  C, Mirand  A, Lukashev  A. TerletskaiaLadwig E, Farkas A, Schuffenecker I, et al. Transmission patterns of human enterovirus 71 to, from and among European countries, 2003 to 2013. Euro Surveill. 2015;20:pi=30005. DOIPubMedGoogle Scholar
  8. Tee  KK, Lam  TT, Chan  YF, Bible  JM, Kamarulzaman  A, Tong  CY, Evolutionary genetics of human enterovirus 71: origin, population dynamics, natural selection, and seasonal periodicity of the VP1 gene. J Virol. 2010;84:333950. DOIPubMedGoogle Scholar
  9. Kroneman  A, Vennema  H, Deforche  K. Avoort Hvd, Peñaranda S, Oberste MS, et al. An automated genotyping tool for enteroviruses and noroviruses. J Clin Virol. 2011;51:121–5. DOIPubMedGoogle Scholar
  10. Tong  CY, Bible  JM, Platt  C. A fatal case of enterovirus 71 infection with a single nucleotide variation in domain V of the 5′ untranslated region. Pediatr Infect Dis J. 2011;30:10134. DOIPubMedGoogle Scholar

Top

Figure

Top

Cite This Article

DOI: 10.3201/eid2210.160357

1Contributing members of the Laboratory Network for Enterovirus Diagnostics are listed at the end of this article.

Related Links

Top

Table of Contents – Volume 22, Number 10—October 2016

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.

Top

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Sabine Diedrich, National Reference Centre for Poliomyelitis and Enteroviruses, Robert Koch Institute, Seestraße 10, 13353 Berlin, Germany

Send To

10000 character(s) remaining.

Top

Page created: September 20, 2016
Page updated: September 20, 2016
Page reviewed: September 20, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external